PB101 developers

Panolos Bioscience is a South Korean biotechnology company specializing in the development of multi-target protein therapeutics for oncology and ophthalmology. The company's core technology, the αART (Anti-Angiogenesis-based Recombinant Trap) platform, enables the design of multi-specific fusion proteins that can simultaneously target various pathways involved in disease progression. Its lead candidate, PB101, is a VEGF-Trap designed to neutralize all isoforms of VEGF and PlGF with high affinity, currently being evaluated in clinical trials for solid tumors. Panolos aims to overcome the limitations of existing anti-angiogenic therapies by providing superior binding profiles and enhanced therapeutic efficacy.